CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients

Seung Hyun Kim, Young Min Ye, Gyu Young Hur, Soo Keol Lee, Anthony P. Sampson, Hyun Young Lee, Hae Sim Park

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objectives: Leukotriene receptor antagonists (LTRA), such as montelukast, have been used as a first-line treatment for patients with aspirin-intolerant asthma (AIA). This study evaluated associations between the clinical requirement for LTRA and genetic polymorphisms of the ALOX5, LTC4S, COX-2, CysLTR1 and TBXA2R genes in the arachidonic acid cascade in the long-term management of 89 AIA patients from a Korean population. Methods: Asthma control status was monitored for 1 year with maintenance medications of inhaled corticosteroid and oral LTRA, and AIA patients were classified into three groups according to the mean montelukast dose required per month to maintain asthma control for 1 year: group I (≥200 mg montelukast/month; n = 37), group II (5-150 mg/month; n = 25) and group III (<5 mg/month; n = 27). Genetic polymorphisms in the arachidonic acid cascade were determined using a single-base extension method. Results: We found that there was a significant difference in the genotype frequency of the CysLTR1 promoter polymorphism -634C > T among the three groups (p = 0.007 for group I vs group II, p = 0.017 for group I vs group III), while there were no significant associations between LTRA requirements and polymorphisms of the other genes. The patients with the variant genotype (CT or TT) of the -634C = T CysLTR1 promoter polymorphism showed a higher expression level than those with the common genotype (CC). Conclusion: These findings indicate that the CysLTR1 promoter polymorphism is a useful genetic marker for predicting LTRA requirements in the long-term management of AIA patients.

Original languageEnglish
Pages (from-to)1143-1150
Number of pages8
JournalPharmacogenomics
Volume8
Issue number9
DOIs
Publication statusPublished - 2007 Sep 1
Externally publishedYes

Fingerprint

Leukotriene Antagonists
montelukast
Aspirin
Asthma
Genotype
Genetic Polymorphisms
Genetic Markers
Arachidonic Acid
Genes
Adrenal Cortex Hormones
Maintenance
Population

Keywords

  • Aspirin-intolerant
  • Asthma
  • Cysteinyl leukotriene receptor 1
  • Genetic polymorphism
  • Leukotriene receptor antagonist

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. / Kim, Seung Hyun; Ye, Young Min; Hur, Gyu Young; Lee, Soo Keol; Sampson, Anthony P.; Lee, Hyun Young; Park, Hae Sim.

In: Pharmacogenomics, Vol. 8, No. 9, 01.09.2007, p. 1143-1150.

Research output: Contribution to journalArticle

Kim, Seung Hyun ; Ye, Young Min ; Hur, Gyu Young ; Lee, Soo Keol ; Sampson, Anthony P. ; Lee, Hyun Young ; Park, Hae Sim. / CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. In: Pharmacogenomics. 2007 ; Vol. 8, No. 9. pp. 1143-1150.
@article{9ff9d8bb884741269f61992a87fef374,
title = "CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients",
abstract = "Objectives: Leukotriene receptor antagonists (LTRA), such as montelukast, have been used as a first-line treatment for patients with aspirin-intolerant asthma (AIA). This study evaluated associations between the clinical requirement for LTRA and genetic polymorphisms of the ALOX5, LTC4S, COX-2, CysLTR1 and TBXA2R genes in the arachidonic acid cascade in the long-term management of 89 AIA patients from a Korean population. Methods: Asthma control status was monitored for 1 year with maintenance medications of inhaled corticosteroid and oral LTRA, and AIA patients were classified into three groups according to the mean montelukast dose required per month to maintain asthma control for 1 year: group I (≥200 mg montelukast/month; n = 37), group II (5-150 mg/month; n = 25) and group III (<5 mg/month; n = 27). Genetic polymorphisms in the arachidonic acid cascade were determined using a single-base extension method. Results: We found that there was a significant difference in the genotype frequency of the CysLTR1 promoter polymorphism -634C > T among the three groups (p = 0.007 for group I vs group II, p = 0.017 for group I vs group III), while there were no significant associations between LTRA requirements and polymorphisms of the other genes. The patients with the variant genotype (CT or TT) of the -634C = T CysLTR1 promoter polymorphism showed a higher expression level than those with the common genotype (CC). Conclusion: These findings indicate that the CysLTR1 promoter polymorphism is a useful genetic marker for predicting LTRA requirements in the long-term management of AIA patients.",
keywords = "Aspirin-intolerant, Asthma, Cysteinyl leukotriene receptor 1, Genetic polymorphism, Leukotriene receptor antagonist",
author = "Kim, {Seung Hyun} and Ye, {Young Min} and Hur, {Gyu Young} and Lee, {Soo Keol} and Sampson, {Anthony P.} and Lee, {Hyun Young} and Park, {Hae Sim}",
year = "2007",
month = "9",
day = "1",
doi = "10.2217/14622416.8.9.1143",
language = "English",
volume = "8",
pages = "1143--1150",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients

AU - Kim, Seung Hyun

AU - Ye, Young Min

AU - Hur, Gyu Young

AU - Lee, Soo Keol

AU - Sampson, Anthony P.

AU - Lee, Hyun Young

AU - Park, Hae Sim

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Objectives: Leukotriene receptor antagonists (LTRA), such as montelukast, have been used as a first-line treatment for patients with aspirin-intolerant asthma (AIA). This study evaluated associations between the clinical requirement for LTRA and genetic polymorphisms of the ALOX5, LTC4S, COX-2, CysLTR1 and TBXA2R genes in the arachidonic acid cascade in the long-term management of 89 AIA patients from a Korean population. Methods: Asthma control status was monitored for 1 year with maintenance medications of inhaled corticosteroid and oral LTRA, and AIA patients were classified into three groups according to the mean montelukast dose required per month to maintain asthma control for 1 year: group I (≥200 mg montelukast/month; n = 37), group II (5-150 mg/month; n = 25) and group III (<5 mg/month; n = 27). Genetic polymorphisms in the arachidonic acid cascade were determined using a single-base extension method. Results: We found that there was a significant difference in the genotype frequency of the CysLTR1 promoter polymorphism -634C > T among the three groups (p = 0.007 for group I vs group II, p = 0.017 for group I vs group III), while there were no significant associations between LTRA requirements and polymorphisms of the other genes. The patients with the variant genotype (CT or TT) of the -634C = T CysLTR1 promoter polymorphism showed a higher expression level than those with the common genotype (CC). Conclusion: These findings indicate that the CysLTR1 promoter polymorphism is a useful genetic marker for predicting LTRA requirements in the long-term management of AIA patients.

AB - Objectives: Leukotriene receptor antagonists (LTRA), such as montelukast, have been used as a first-line treatment for patients with aspirin-intolerant asthma (AIA). This study evaluated associations between the clinical requirement for LTRA and genetic polymorphisms of the ALOX5, LTC4S, COX-2, CysLTR1 and TBXA2R genes in the arachidonic acid cascade in the long-term management of 89 AIA patients from a Korean population. Methods: Asthma control status was monitored for 1 year with maintenance medications of inhaled corticosteroid and oral LTRA, and AIA patients were classified into three groups according to the mean montelukast dose required per month to maintain asthma control for 1 year: group I (≥200 mg montelukast/month; n = 37), group II (5-150 mg/month; n = 25) and group III (<5 mg/month; n = 27). Genetic polymorphisms in the arachidonic acid cascade were determined using a single-base extension method. Results: We found that there was a significant difference in the genotype frequency of the CysLTR1 promoter polymorphism -634C > T among the three groups (p = 0.007 for group I vs group II, p = 0.017 for group I vs group III), while there were no significant associations between LTRA requirements and polymorphisms of the other genes. The patients with the variant genotype (CT or TT) of the -634C = T CysLTR1 promoter polymorphism showed a higher expression level than those with the common genotype (CC). Conclusion: These findings indicate that the CysLTR1 promoter polymorphism is a useful genetic marker for predicting LTRA requirements in the long-term management of AIA patients.

KW - Aspirin-intolerant

KW - Asthma

KW - Cysteinyl leukotriene receptor 1

KW - Genetic polymorphism

KW - Leukotriene receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=35348879781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348879781&partnerID=8YFLogxK

U2 - 10.2217/14622416.8.9.1143

DO - 10.2217/14622416.8.9.1143

M3 - Article

VL - 8

SP - 1143

EP - 1150

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 9

ER -